Brought to you by 
Trinity Biotech buys Fiomi Diagnostics for $13.1mm in cash, stock, and earn-outs
26 Feb 2014
Executive Summary
Trinity Biotech PLC (point-of-care and clinical laboratory diagnostics) has acquired Fiomi Diagnostics AB for $13.1mm, with $9.7mm up front ($5.6mm will be in cash and $4.1mm in 408k Trinity Biotech ADRs) and $3.4mm in earn-outs (for getting the CE Mark, FDA submission, and FDA approval of a troponin I assay).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Trinity Biotech buys Fiomi Diagnostics for $13.1mm in cash, stock, and earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice